• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

    2/29/24 7:57:00 AM ET
    $MOTS
    Medical/Dental Instruments
    Health Care
    Get the next $MOTS alert in real time by email

    Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth

    EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer.

    Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical device imaging. Furthermore, Mr. Aldrich is a seasoned executive with experience in startup organizations, as well as, small/mid cap companies that are both privately and publicly held. He has established a reputation as an authentic leader with the ability to drive execution through clear organizational vision.

    Mr Aldrich remarked, "I am honored and humbled to be able to assume the role of CEO. Stephen has done a remarkable job in getting EndoSound so far in its journey. EndoSound EVS™ is a customer-focused product that can reduce aggregate healthcare costs and improve patient experience and lives. It is exciting to be bringing this technology that so clearly can transform the GI market and patient access to endoscopic ultrasound to market. I look forward to working closely with the EndoSound Board of Directors, Stephen, and the rest of the EndoSound team in successfully launching EVS and making the company's immense potential a reality."

    Stephen Steinberg, MD commented, "We are thrilled to welcome Scott to the team. He brings a wealth of knowledge in areas that will be extremely important to EndoSound's success. We believe his leadership style, business acumen and passion make him more than capable to build and grow a revolutionary medical device company."

    About EndoSound

    EndoSound, Inc., is a privately held company based in Portland, Oregon. EndoSound is dedicated to expanding access to endoscopic ultrasound technology around the world. With its patented design, EndoSound transforms any flexible upper endoscope into a fully functional EUS scope. It is comprised of an experienced team of scientists and engineers, clinicians, and seasoned business professionals with a track record of bringing new medical devices to market.

    To learn more about the EVS, please visit endosound.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240229798769/en/

    Get the next $MOTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOTS

    DatePrice TargetRatingAnalyst
    1/25/2023Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $MOTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Motus GI downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Motus GI from Buy to Neutral

      1/25/23 9:38:23 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.

      SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

      11/14/24 4:22:34 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Motus GI Holdings Inc.

      SC 13G - Motus GI Holdings, Inc. (0001686850) (Subject)

      2/14/24 3:44:05 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Motus GI Holdings, Inc. (Amendment)

      SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

      12/29/21 4:28:32 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Motus GI Holdings Inc.

      EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)

      8/14/24 12:15:04 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Motus GI Holdings Inc.

      EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)

      8/14/24 12:15:07 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Motus GI Holdings Inc.

      EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)

      8/14/24 12:15:02 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q

      5/14/24 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

      Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a

      3/18/24 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

      Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi

      2/29/24 7:57:00 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Durbin Scott

      4 - Motus GI Holdings, Inc. (0001686850) (Issuer)

      3/13/24 4:05:19 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Nelson Sonja

      4 - Motus GI Holdings, Inc. (0001686850) (Issuer)

      3/13/24 8:03:48 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Pruden Gary J

      4 - Motus GI Holdings, Inc. (0001686850) (Issuer)

      3/13/24 8:02:41 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Financials

    Live finance-specific insights

    See more
    • Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q

      5/14/24 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company is actively supporting its existing installed customer base and pipeline opportunities in contracted health systems  The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures, and expects submission to FDA by the end of 2023 FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and e

      3/31/23 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update

      Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's historyRecently named a Sole Source Supplier by the Department of Veteran's Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designationPresented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populations FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSW

      11/14/22 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Leadership Updates

    Live Leadership Updates

    See more
    • EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

      Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi

      2/29/24 7:57:00 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

      FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi

      9/6/23 5:00:42 PM ET
      $MOTS
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

      Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa

      6/7/23 8:30:00 AM ET
      $MOTS
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products